Skip to main content
Fig. 5 | The Journal of Headache and Pain

Fig. 5

From: Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine

Fig. 5

Proportions of subjects experiencing relief from symptoms associated with migraine at 60 min postdose.a Legend: SC, subcutaneous. a1 subject randomized to 6 mg only treated 1 attack. b3 mg n  =  8; 6 mg n  =  10. c3 mg n  =  9; 6 mg n  =  11. d3 mg n  =  10; 6 mg n  =  9

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us